Clinical Trials Browser

Phase 1/2 × OTHER × PHY 906 × Clear all

NCT00411762 2015-03-27

A Phase I/II, Multi-Center, Open-Label, Dose-Escalation, Safety and Efficacy Study of PHY906 Plus Capecitabine in Patients With Advanced Pancreatic Carcinoma

Phase 1/2 Completed

25 enrolled 5 charts

Gastrointestinal

Pancreatic Neoplasms